特异性-话题@MedSci

#特异性#

563篇内容 | 2727人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1899440, encodeId=d647189944041, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, objectTitle=Nature Cancer：iNKT细胞疗法“新兵”——双特异性抗体, objectType=article, longId=203619, objectId=306220361914, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=306220361914, replyNumber=0, likeNumber=100, createdTime=2021-03-10, rootId=0, userName=jinweidong, userId=dc7a157, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=306220361914, moduleTitle=Nature Cancer：iNKT细胞疗法“新兵”——双特异性抗体, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=306220361914)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1899346, encodeId=a8d91899346ba, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, objectTitle=新发现！三特异性抗体可提高T细胞抗癌疗效, objectType=article, longId=184234, objectId=bdad1842343b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdad1842343b, replyNumber=0, likeNumber=76, createdTime=2020-10-27, rootId=0, userName=jinweidong, userId=dc7a157, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdad1842343b, moduleTitle=新发现！三特异性抗体可提高T细胞抗癌疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdad1842343b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1899422, encodeId=215418994220f, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, objectTitle=Diabetologia：胰岛素抵抗与慢性肾病和肾功能的性别特异性关联:一项双向孟德尔随机研究, objectType=article, longId=200088, objectId=213b200088f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=213b200088f2, replyNumber=0, likeNumber=64, createdTime=2021-02-20, rootId=0, userName=jinweidong, userId=dc7a157, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=213b200088f2, moduleTitle=Diabetologia：胰岛素抵抗与慢性肾病和肾功能的性别特异性关联:一项双向孟德尔随机研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=213b200088f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1899387, encodeId=b17b189938eb0, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, objectTitle=合作开发双特异性抗体！艾伯维向Genmab预付款高达7.5亿美元, objectType=article, longId=195642, objectId=43db195642e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43db195642e7, replyNumber=0, likeNumber=86, createdTime=2021-03-05, rootId=0, userName=jinweidong, userId=dc7a157, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43db195642e7, moduleTitle=合作开发双特异性抗体！艾伯维向Genmab预付款高达7.5亿美元, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43db195642e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1899426, encodeId=878b1899426d6, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, objectTitle=EBV特异性T细胞免疫疗法ATA188治疗多发性硬化症：所有剂量组均取得积极结果, objectType=article, longId=200586, objectId=adbc20058698, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=adbc20058698, replyNumber=0, likeNumber=86, createdTime=2020-12-24, rootId=0, userName=jinweidong, userId=dc7a157, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=adbc20058698, moduleTitle=EBV特异性T细胞免疫疗法ATA188治疗多发性硬化症：所有剂量组均取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=adbc20058698)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1899347, encodeId=2b87189934efb, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, objectTitle=BMC Pediatr：儿科中特异性疾病与贫血相关性研究, objectType=article, longId=184653, objectId=faa21846538b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=faa21846538b, replyNumber=0, likeNumber=72, createdTime=2020-02-16, rootId=0, userName=jinweidong, userId=dc7a157, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=faa21846538b, moduleTitle=BMC Pediatr：儿科中特异性疾病与贫血相关性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=faa21846538b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1899386, encodeId=72eb18993866b, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, objectTitle=SCIENCE：人类肿瘤细胞内的细菌竟有细胞特异性！, objectType=article, longId=194974, objectId=3fee1949e431, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fee1949e431, replyNumber=0, likeNumber=69, createdTime=2021-03-18, rootId=0, userName=jinweidong, userId=dc7a157, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fee1949e431, moduleTitle=SCIENCE：人类肿瘤细胞内的细菌竟有细胞特异性！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fee1949e431)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1899430, encodeId=b3e418994309d, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, objectTitle=Nat Med：抗HIV-1抗体联合治疗与病毒特异性T细胞免疫力增强相关, objectType=article, longId=201414, objectId=04e72014140f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04e72014140f, replyNumber=0, likeNumber=66, createdTime=2020-11-05, rootId=0, userName=jinweidong, userId=dc7a157, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04e72014140f, moduleTitle=Nat Med：抗HIV-1抗体联合治疗与病毒特异性T细胞免疫力增强相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04e72014140f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1899358, encodeId=be61189935808, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, objectTitle=Clinica Chimica Acta：在Immulite®2000XPi分析仪上的总免疫球蛋白和特异性免疫球蛋白E第三方验证, objectType=article, longId=188336, objectId=ebaa1883368c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebaa1883368c, replyNumber=0, likeNumber=63, createdTime=2020-06-08, rootId=0, userName=jinweidong, userId=dc7a157, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebaa1883368c, moduleTitle=Clinica Chimica Acta：在Immulite®2000XPi分析仪上的总免疫球蛋白和特异性免疫球蛋白E第三方验证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ebaa1883368c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1899384, encodeId=433c18993840a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, objectTitle=Radiology：FDG PET/MRI联合肝细胞特异性对比剂在直肠癌M分期的价值, objectType=article, longId=194576, objectId=9f0e1945e631, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f0e1945e631, replyNumber=0, likeNumber=68, createdTime=2020-08-30, rootId=0, userName=jinweidong, userId=dc7a157, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f0e1945e631, moduleTitle=Radiology：FDG PET/MRI联合肝细胞特异性对比剂在直肠癌M分期的价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f0e1945e631)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1899415, encodeId=5e2718994153f, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, objectTitle=Nat Commun：肠道微生物共丰度网络在炎症性肠病和肥胖中的特异性, objectType=article, longId=199524, objectId=f08619952481, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f08619952481, replyNumber=0, likeNumber=75, createdTime=2020-11-04, rootId=0, userName=jinweidong, userId=dc7a157, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f08619952481, moduleTitle=Nat Commun：肠道微生物共丰度网络在炎症性肠病和肥胖中的特异性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f08619952481)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1899375, encodeId=b6c318993e5f8, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, objectTitle=Nat Commun：前列腺特异性抗原动态能够预测个体对间歇性雄激素阻断治疗的个体响应 , objectType=article, longId=192841, objectId=60cc192841a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60cc192841a6, replyNumber=0, likeNumber=94, createdTime=2021-03-21, rootId=0, userName=jinweidong, userId=dc7a157, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60cc192841a6, moduleTitle=Nat Commun：前列腺特异性抗原动态能够预测个体对间歇性雄激素阻断治疗的个体响应 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60cc192841a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1899425, encodeId=97371899425a6, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, objectTitle=康宁杰瑞PD-L1/CTLA-4双特异性抗体获FDA孤儿药资格认定, objectType=article, longId=200285, objectId=7fde2002858b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fde2002858b, replyNumber=0, likeNumber=73, createdTime=2020-09-29, rootId=0, userName=jinweidong, userId=dc7a157, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fde2002858b, moduleTitle=康宁杰瑞PD-L1/CTLA-4双特异性抗体获FDA孤儿药资格认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fde2002858b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1899421, encodeId=0c7a18994215f, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, objectTitle=JAMA Intern Med：新冠肺炎康复患者体内的特异性中和抗体滴度研究, objectType=article, longId=199922, objectId=44f7199922b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44f7199922b3, replyNumber=0, likeNumber=74, createdTime=2020-12-09, rootId=0, userName=jinweidong, userId=dc7a157, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44f7199922b3, moduleTitle=JAMA Intern Med：新冠肺炎康复患者体内的特异性中和抗体滴度研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44f7199922b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1899400, encodeId=136b1899400b8, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, objectTitle=凌腾医药开展双特异性抗体用于胃癌全球临床3期试验, objectType=article, longId=197578, objectId=232d19e5785e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=232d19e5785e, replyNumber=0, likeNumber=79, createdTime=2021-04-16, rootId=0, userName=jinweidong, userId=dc7a157, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=232d19e5785e, moduleTitle=凌腾医药开展双特异性抗体用于胃癌全球临床3期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=232d19e5785e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1899390, encodeId=807518993902c, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, objectTitle=EHA 2020：罗氏的CD20xCD3双特异性抗体glofitamab治疗淋巴瘤的新近进展, objectType=article, longId=195825, objectId=27f019582522, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27f019582522, replyNumber=0, likeNumber=64, createdTime=2020-10-21, rootId=0, userName=jinweidong, userId=dc7a157, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27f019582522, moduleTitle=EHA 2020：罗氏的CD20xCD3双特异性抗体glofitamab治疗淋巴瘤的新近进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27f019582522)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1899403, encodeId=04ea18994036d, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, objectTitle=三功能双特异性抗体Catumaxomab治疗腹膜癌，获得NMPA授权开始全球性3期临床试验, objectType=article, longId=197631, objectId=9f1c19e631bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f1c19e631bf, replyNumber=0, likeNumber=64, createdTime=2021-01-01, rootId=0, userName=jinweidong, userId=dc7a157, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f1c19e631bf, moduleTitle=三功能双特异性抗体Catumaxomab治疗腹膜癌，获得NMPA授权开始全球性3期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f1c19e631bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1899350, encodeId=694f189935054, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, objectTitle=Blood： CD19特异性CAR T细胞疗法治疗R/R B-ALL, objectType=article, longId=185565, objectId=07da185565a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07da185565a3, replyNumber=0, likeNumber=67, createdTime=2020-01-03, rootId=0, userName=jinweidong, userId=dc7a157, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07da185565a3, moduleTitle=Blood： CD19特异性CAR T细胞疗法治疗R/R B-ALL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=07da185565a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1899361, encodeId=5c191899361fe, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, objectTitle=强生的EGFR-MET双特异性抗体JNJ-6372治疗非小细胞肺癌，获得FDA的突破性疗法称号, objectType=article, longId=189903, objectId=463418990337, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=463418990337, replyNumber=0, likeNumber=79, createdTime=2020-06-27, rootId=0, userName=jinweidong, userId=dc7a157, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=463418990337, moduleTitle=强生的EGFR-MET双特异性抗体JNJ-6372治疗非小细胞肺癌，获得FDA的突破性疗法称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=463418990337)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1899383, encodeId=2293189938330, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, objectTitle=双特异性抗体Faricimab治疗AMD的Ⅲ期数据公布，16周仅需给药1次, objectType=article, longId=194142, objectId=365c1941420a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=365c1941420a, replyNumber=0, likeNumber=0, createdTime=2020-10-24, rootId=0, userName=jinweidong, userId=dc7a157, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=365c1941420a, moduleTitle=双特异性抗体Faricimab治疗AMD的Ⅲ期数据公布，16周仅需给药1次, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=365c1941420a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

特异性

2020-05-29

jinweidong (审核中...)

前往app查看评论内容

#特异性#

Nature Cancer：iNKT细胞疗法“新兵”——双特异性抗体

2021-03-10

jinweidong (审核中...)

前往app查看评论内容

#特异性#

新发现！三特异性抗体可提高T细胞抗癌疗效

2020-10-27

jinweidong (审核中...)

前往app查看评论内容

#特异性#

Diabetologia：胰岛素抵抗与慢性肾病和肾功能的性别特异性关联:一项双向孟德尔随机研究

2021-02-20

jinweidong (审核中...)

前往app查看评论内容

#特异性#

合作开发双特异性抗体！艾伯维向Genmab预付款高达7.5亿美元

2021-03-05

jinweidong (审核中...)

前往app查看评论内容

#特异性#

EBV特异性T细胞免疫疗法ATA188治疗多发性硬化症：所有剂量组均取得积极结果

2020-12-24

jinweidong (审核中...)

前往app查看评论内容

#特异性#

BMC Pediatr：儿科中特异性疾病与贫血相关性研究

2020-02-16

jinweidong (审核中...)

前往app查看评论内容

#特异性#

SCIENCE：人类肿瘤细胞内的细菌竟有细胞特异性！

2021-03-18

jinweidong (审核中...)

前往app查看评论内容

#特异性#

Nat Med：抗HIV-1抗体联合治疗与病毒特异性T细胞免疫力增强相关

2020-11-05

jinweidong (审核中...)

前往app查看评论内容

#特异性#

Clinica Chimica Acta：在Immulite®2000XPi分析仪上的总免疫球蛋白和特异性免疫球蛋白E第三方验证

2020-06-08

jinweidong (审核中...)

前往app查看评论内容

#特异性#

Radiology：FDG PET/MRI联合肝细胞特异性对比剂在直肠癌M分期的价值

2020-08-30

jinweidong (审核中...)

前往app查看评论内容

#特异性#

Nat Commun：肠道微生物共丰度网络在炎症性肠病和肥胖中的特异性

2020-11-04

jinweidong (审核中...)

前往app查看评论内容

#特异性#

Nat Commun：前列腺特异性抗原动态能够预测个体对间歇性雄激素阻断治疗的个体响应

2021-03-21

jinweidong (审核中...)

前往app查看评论内容

#特异性#

康宁杰瑞PD-L1/CTLA-4双特异性抗体获FDA孤儿药资格认定

2020-09-29

jinweidong (审核中...)

前往app查看评论内容

#特异性#

JAMA Intern Med：新冠肺炎康复患者体内的特异性中和抗体滴度研究

2020-12-09

jinweidong (审核中...)

前往app查看评论内容

#特异性#

凌腾医药开展双特异性抗体用于胃癌全球临床3期试验

2021-04-16

jinweidong (审核中...)

前往app查看评论内容

#特异性#

EHA 2020：罗氏的CD20xCD3双特异性抗体glofitamab治疗淋巴瘤的新近进展

2020-10-21

jinweidong (审核中...)

前往app查看评论内容

#特异性#

三功能双特异性抗体Catumaxomab治疗腹膜癌，获得NMPA授权开始全球性3期临床试验

2021-01-01

jinweidong (审核中...)

前往app查看评论内容

#特异性#

Blood： CD19特异性CAR T细胞疗法治疗R/R B-ALL

2020-01-03

jinweidong (审核中...)

前往app查看评论内容

#特异性#

强生的EGFR-MET双特异性抗体JNJ-6372治疗非小细胞肺癌，获得FDA的突破性疗法称号

2020-06-27

jinweidong (审核中...)

前往app查看评论内容

#特异性#

双特异性抗体Faricimab治疗AMD的Ⅲ期数据公布，16周仅需给药1次

2020-10-24

科室
- - 订阅+
  - 更多科室
工具
服务